收费全文 | 13520篇 |
免费 | 1852篇 |
国内免费 | 352篇 |
耳鼻咽喉 | 438篇 |
儿科学 | 278篇 |
妇产科学 | 114篇 |
基础医学 | 2247篇 |
口腔科学 | 63篇 |
临床医学 | 1696篇 |
内科学 | 1334篇 |
皮肤病学 | 127篇 |
神经病学 | 328篇 |
特种医学 | 662篇 |
外国民族医学 | 16篇 |
外科学 | 1778篇 |
综合类 | 2511篇 |
预防医学 | 537篇 |
眼科学 | 223篇 |
药学 | 723篇 |
17篇 | |
中国医学 | 305篇 |
肿瘤学 | 2327篇 |
2024年 | 211篇 |
2023年 | 357篇 |
2022年 | 631篇 |
2021年 | 787篇 |
2020年 | 793篇 |
2019年 | 632篇 |
2018年 | 576篇 |
2017年 | 624篇 |
2016年 | 722篇 |
2015年 | 651篇 |
2014年 | 963篇 |
2013年 | 843篇 |
2012年 | 717篇 |
2011年 | 770篇 |
2010年 | 580篇 |
2009年 | 491篇 |
2008年 | 528篇 |
2007年 | 518篇 |
2006年 | 482篇 |
2005年 | 408篇 |
2004年 | 359篇 |
2003年 | 326篇 |
2002年 | 277篇 |
2001年 | 249篇 |
2000年 | 236篇 |
1999年 | 189篇 |
1998年 | 187篇 |
1997年 | 149篇 |
1996年 | 152篇 |
1995年 | 147篇 |
1994年 | 125篇 |
1993年 | 125篇 |
1992年 | 98篇 |
1991年 | 94篇 |
1990年 | 76篇 |
1989年 | 68篇 |
1988年 | 61篇 |
1987年 | 50篇 |
1986年 | 73篇 |
1985年 | 70篇 |
1984年 | 49篇 |
1983年 | 28篇 |
1982年 | 42篇 |
1981年 | 49篇 |
1980年 | 37篇 |
1979年 | 21篇 |
1978年 | 26篇 |
1977年 | 30篇 |
1976年 | 10篇 |
1975年 | 15篇 |
Aims
The 2014 British Thyroid Association thyroid cancer guidelines recommend lifelong follow-up of thyroid cancer patients. This is probably unnecessary, can cause patient anxiety, is time consuming and places significant demand on National Health Service resources. It has been suggested that low-risk differentiated thyroid cancer (DTC) patients could be discharged to primary care once they are 5 years from diagnosis and treatment. The aim of this study was to investigate the potential safety of this practice.Materials and methods
In total, 756 patients with dynamically risk-stratified (DRS) low-risk/excellent response to treatment DTC treated over 2001–2013 in the Leeds region were followed after diagnostic surgery and the recurrence rate calculated.Results
The median follow-up time was nearly 10 years (5–17 years). Radiological recurrence occurred in 13/756 (1.7%) patients and was always preceded by raised thyroglobulin/ thyroglobulin antibody levels. In all 13 patients elevation of thyroglobulin occurred within 5 years of diagnosis. Two additional patients were found to have rising thyroglobulin at almost 9 and 10.5 years from diagnosis, although to date radiological recurrence has not been detected. Assuming these two patients developed recurrence with longer duration of follow-up, then 0.26% (2/756) of patients would not have their recurrence discovered within 5 years of diagnosis. To detect 100% of patients with a putative recurrence in our cohort would require 10.5 years of follow-up. Four patients had transiently raised thyroglobulin, which became undetectable within 2 years (in three patients), without any treatment and radiological recurrence was not discovered.Conclusion
Discharge of DRS low-risk DTC patients to primary care after 5 years of secondary care follow-up is reasonable, accepting that late recurrence may occur in a very small minority of individuals (0.26%, ~1:400). A more cautious approach would be to continue monitoring for 10 years, although the frequency of assessments could be reduced with increasing duration of follow-up. 相似文献Materials and Methods: Relevant papers in PubMed published through June 2017 were selected to track updated information about PTL with an emphasis on diagnosis and novel therapeutic management.
Results: The most frequent cases include non-Hodgkin lymphoma derived from B-cells, mainly diffuse large B-cell lymphoma (DLBCL) followed by mucosa-associated lymphoid tissue (MALT) lymphoma or a mixed type. Other subtypes are less common. Lymphomas derived from T-cells and Hodgkin lymphomas are extremely rare. Hashimoto's autoimmune thyroiditis has been implicated as a risk factor for lymphoma. At the molecular level, the Wnt5a protein and its receptor Ror2 are involved in the course of the disease. Ultrasonography, fine needle aspiration (FNA) biopsy, and core or open biopsy combined with new diagnostic facilities contribute to an accurate diagnosis. An increased potential exists for a cure without the need for a radical surgical procedure. Modern chemoradiation therapy plus the monoclonal antibody rituximab, which acts against CD20, have limited the need for surgical interventions and provide an excellent outcome in most cases. However, some cases have resulted in treatment failure or recurrence.
Conclusions: A multidisciplinary approach must be used to define the management policy in each case. Future efforts by researchers are likely to be focused on the molecular level. 相似文献